Natixis Advisors LLC grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 53.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,625 shares of the biotechnology company's stock after buying an additional 11,731 shares during the period. Natixis Advisors LLC owned 0.06% of Repligen worth $5,004,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Andra AP fonden acquired a new position in shares of Repligen in the 2nd quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new position in shares of Repligen in the 2nd quarter valued at $33,000. UMB Bank n.a. raised its holdings in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after buying an additional 130 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after buying an additional 136 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
RGEN has been the topic of a number of research analyst reports. UBS Group cut their target price on shares of Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Wednesday, July 31st. Royal Bank of Canada reiterated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price on the stock. Finally, Benchmark reaffirmed a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.
View Our Latest Report on Repligen
Repligen Stock Up 0.6 %
NASDAQ:RGEN traded up $0.82 on Friday, hitting $142.58. The stock had a trading volume of 556,879 shares, compared to its average volume of 706,303. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The firm's fifty day simple moving average is $140.26 and its two-hundred day simple moving average is $143.44. The stock has a market cap of $7.99 billion, a P/E ratio of -385.34, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 10.44.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.23 EPS. Analysts predict that Repligen Co. will post 1.52 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
